KMT2A and acute myeloid leukemia: A phase I/II study evaluated the combination of Revumenib with decitabine/cedazuridine and Venetoclax in R/R AML patients (NPM1-mutant, KMT2A-rearranged, and NUP98-rearranged), reporting an ORR of 88%, with a CR + CRi of 58%, and with a rate of MRD negativity according to flow cytometry of 93% among the patients with CR + CRi [105].